Navarra, Pierluigi

Navarra, Pierluigi  

ROMA - Dipartimento di Sicurezza e Bioetica  

Mostra records
Risultati 1 - 20 di 147 (tempo di esecuzione: 0.031 secondi).
Data di pubblicazione Titolo Autore(i) File
1-gen-2023 Drug Repurposing in Pediatric Brain Tumors: Posterior Fossa Ependymoma and Diffuse Midline Glioma under the Looking Glass Servidei, Tiziana; Sgambato, Alessandro; Lucchetti, Donatella; Navarra, Pierluigi; Ruggiero, Antonio
1-gen-2023 Emerging Perspectives on the Antiparasitic Mebendazole as a Repurposed Drug for the Treatment of Brain Cancers Meco, Daniela; Attinà, Giorgio; Mastrangelo, Stefano; Navarra, Pierluigi; Ruggiero, Antonio
1-gen-2023 mTOR Inhibition Is Effective against Growth, Survival and Migration, but Not against Microglia Activation in Preclinical Glioma Models Lisi, Lucia; Pizzoferrato, Michela; Ciotti, Gabriella Maria Pia; Martire, Maria; Navarra, Pierluigi
1-gen-2023 REMIFENTANIL DOES NOT AFFECT HUMAN MICROGLIAL IMMUNE ACTIVATION IN RESPONSE TO PRO-INFLAMMATORY CYTOKINES Dello Russo, Cinzia; Cappoli, Natalia; Tabolacci, Elisabetta; Sollazzi, Liliana; Navarra, Pierluigi; Aceto, Paola
1-gen-2023 Use of High-Dose Nebulized Colistimethate in Patients with Colistin-Only Susceptible Acinetobacter baumannii VAP: Clinical, Pharmacokinetic and Microbiome Features De Pascale, Gennaro; Pintaudi, Gabriele; Lisi, Lucia; De Maio, Flavio; Cutuli, Salvatore Lucio; Tanzarella, Eloisa Sofia; Carelli, Simone; Lombardi, Gianmarco; Cesarano, Melania; Gennenzi, Veronica; Ciotti, Gabriella Maria Pia; Grieco, Domenico Luca; Posteraro, Brunella; Sanguinetti, Maurizio; Navarra, Pierluigi; Antonelli, Massimo
1-gen-2023 What is the weight of expectation bias in oncology trials? Dello Russo, Cinzia; Navarra, Pierluigi
1-gen-2022 Clinical experience with CTLA-4 blockade for cancer immunotherapy: From the monospecific monoclonal antibody ipilimumab to probodies and bispecific molecules targeting the tumor microenvironment Lisi, Lucia; Lacal, P. M.; Martire, Maria; Navarra, Pierluigi; Graziani, Giovanni
1-gen-2022 Extended-release calcifediol in stage 3–4 chronic kidney disease: a new therapy for the treatment of secondary hyperparathyroidism associated with hypovitaminosis D Cozzolino, M.; Minghetti, P.; Navarra, Pierluigi
1-gen-2022 Local Investigators Significantly Overestimate Overall Response Rates Compared to Blinded Independent Central Reviews in Uncontrolled Oncology Trials: A Comprehensive Review of the Literature Dello Russo, Cinzia; Navarra, Pierluigi
1-gen-2022 The effects of CHF6467, a new mutated form of NGF, on cell models of human glioblastoma. A comparison with wild-type NGF Lisi, Lucia; Ciotti, Gabriella Maria Pia; Chiavari, Marta; Martire, Maria; Navarra, Pierluigi
1-gen-2022 The effects of painless nerve growth factor on human microglia polarization Lisi, Lucia; Marinelli, Silvia; Ciotti, Gabriella Maria Pia; Pizzoferrato, Michela; Palmerio, Federica; Chiavari, Marta; Cattaneo, Antonino; Navarra, Pierluigi
1-gen-2021 Cell-of-origin and genetic, epigenetic, and microenvironmental factors contribute to the intra-tumoral heterogeneity of pediatric intracranial ependymoma Servidei, T.; Lucchetti, D.; Navarra, P.; Sgambato, A.; Riccardi, R.; Ruggiero, A.
1-gen-2021 Compassionate drug uses and saving for the national health system: the case study of Fondazione Policlinico Gemelli Pilunni, D; Daioisio, V; Campopiano, Rina; Pani, Marcello; Navarra, Pierluigi
1-gen-2021 Effects of remifentanil on human C20 microglial pro-inflammatory activation Cappoli, Natalia; Aceto, Paola; Tabolacci, Elisabetta; Mezzogori, D.; Sollazzi, Liliana; Navarra, Pierluigi; Dello Russo, Cinzia
1-gen-2021 Kinetics of Intestinal Presence of Spores Following Oral Administration of Bacillus clausii Formulations: Three Single-Centre, Crossover, Randomised, Open-Label Studies Navarra, Pierluigi; Milleri, S.; Perez III, M.; Uboldi, M. C.; Pellegrino, Paolo; Bois De Fer, B.; Morelli, Lorenzo
1-gen-2021 Local Investigators Significantly Overestimate Overall Response Rates Compared to Blinded Independent Central Reviews in Phase 2 Oncology Trials Dello Russo, Cinzia; Cappoli, Natalia; Pilunni, D.; Navarra, Pierluigi
1-gen-2021 Relationship between injection site reactions and different adalimumab formulations. Analysis of the adverse events reported in Italy in 2016-2019 Pilunni, D.; Santuccio, C.; Sottosanti, Laura; Felicetti, P.; Navarra, Pierluigi
1-gen-2020 A comparison between the assessments of progression-free survival by local investigators versus blinded independent central reviews in phase III oncology trials Dello Russo, Cinzia; Cappoli, Natalia; Navarra, Pierluigi
1-gen-2020 A proof-of-concept study on CGRP plasma levels of migraineurs during a 6-month treatment with ERENUMAB Tringali, Giuseppe; Vollono, Catello; Calabresi, Paolo; Navarra, Pierluigi
1-gen-2020 Beyond antibodies: ankyrins and DARPins. From basic research to drug approval Caputi, A. P.; Navarra, Pierluigi